BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting

BioVie (NASDAQ: BIVI) announced that an abstract from its SUNRISE-PD study of bezisterim (NE3107) in early Parkinson’s disease was accepted for presentation at the American Academy of Neurology Annual Meeting in Chicago, April 18–22, 2026.

Rhea-AI Summary

BioVie (NASDAQ: BIVI) announced that an abstract from its SUNRISE-PD study of bezisterim (NE3107) in early Parkinson’s disease was accepted for presentation at the American Academy of Neurology Annual Meeting in Chicago, April 18–22, 2026.

The poster, titled "A Study of NE3107 (Bezisterim) in Early Parkinson's Disease (SUNRISE-PD): Baseline Demographics and Characteristic," will be presented on Monday, April 20, 5:00–6:00 PM CT. Topline results from SUNRISE-PD are expected in mid‑2026. The AAN represents 44,000+ neurology professionals.

Argus Apr 14 session

+5.80% close to close Open Argus

Details

News Market Reaction – BIVI

On Apr 14, the day this news came out, BIVI closed 5.80% above the previous close.

Data tracked by StockTitan Argus for the Apr 14 session.

Market Context

On Apr 14, the day this news came out, the stock closed 5.8% above the previous close. A strong posi...

Analysis

On Apr 14, the day this news came out, the stock closed 5.8% above the previous close. A strong positive reaction aligns with BioVie’s ongoing visibility push for bezisterim (NE3107). The abstract adds another touchpoint following prior SUNRISE-PD enrollment completion and multiple conference acceptances in early 2026. Historically, similar updates saw modest declines rather than strong gains, so a move of ≥5% would represent a shift in how investors weigh conference presence versus definitive clinical data. Investors may watch for the planned topline SUNRISE-PD results in mid‑2026 as the next major inflection.

Key Figures

AAN 2026 dates: April 18–22, 2026 Poster session time: 5:00–6:00 PM CT AAN membership: 44,000+ members

AAN 2026 dates

April 18–22, 2026

American Academy of Neurology Annual Meeting schedule

Poster session time

5:00–6:00 PM CT

SUNRISE-PD poster on April 20, 2026

AAN membership

44,000+ members

Size of American Academy of Neurology

Historical Context

5 past events · Latest: Mar 12

5 events

1. Mar 12

   Conference abstract

   24h Move

   -1.4%

   SUNRISE-PD abstract acceptance for AD/PD 2026 highlighting baseline demographics.

2. Feb 23

   Investor webinar

   24h Move

   -0.8%

   Announcement of March 4 investor webinar reviewing bezisterim and BIV201 progress.

3. Feb 12

   Conference abstracts

   24h Move

   -3.5%

   Two bezisterim posters accepted for American College of Psychiatrists meeting.

4. Jan 08

   Clinical milestone

   24h Move

   -3.7%

   Completion of enrollment of 60 patients in Phase 2 SUNRISE-PD trial.

5. Nov 19

   Investor webinar

   24h Move

   -4.2%

   December 9, 2025 investor webinar focused on bezisterim and BIV201 programs.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

parkinson’s disease, movement disorders, neurologists

3 terms

parkinson’s disease medical

"bezisterim (NE3107) in the treatment of patients with Parkinson’s Disease at the upcoming"

A progressive brain disorder that gradually impairs movement, balance and certain mental functions by reducing the brain’s ability to produce a chemical important for controlling motion. Investors care because it creates a large, growing market for treatments, devices and care services; success or failure of drugs and clinical trials, regulatory approvals, and long-term care costs can materially affect pharmaceutical and medical-device company valuations.

movement disorders medical

"presented as a poster during the Movement Disorders Session on Parkinson's Disease Emerging"

Movement disorders are a group of neurological conditions that cause problems controlling the speed, smoothness, or rhythm of physical actions—such as tremors, stiffness, slow movement, or involuntary writhing. They matter to investors because they define patient populations, treatment needs, and regulatory pathways; a new therapy that improves mobility can change demand, pricing, and long-term healthcare costs much like a breakthrough in car braking technology changes safety and insurance dynamics.

neurologists medical

"world’s largest association of neurologists and neuroscience professionals with 44,000+ members"

Neurologists are medical doctors who diagnose and treat disorders of the brain, spinal cord, nerves and muscles, ranging from migraines to stroke and neurodegenerative diseases. Investors care because their diagnoses, treatment choices and participation in clinical trials influence the demand for drugs, devices and diagnostics, affect regulatory outcomes and shape how quickly new therapies are adopted—like specialist mechanics whose recommendations determine what repairs and parts a car needs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CARSON CITY, Nev., April 14, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the acceptance of an abstract from its SUNRISE-PD study on lead candidate bezisterim (NE3107) in the treatment of patients with Parkinson’s Disease at the upcoming American Academy of Neurology Annual Meeting (AAN), to be held in Chicago, IL from April 18–22, 2026.

The abstract, titled A Study of NE3107 (Bezisterim) in Early Parkinson's Disease (SUNRISE-PD): Baseline Demographics and Characteristic (J. Palumbo¹, C Ahlem¹, C.L. Reading¹, S. O’Quinn², J. Zhang³, M. Stacy⁴), summarizes the initial data on patients enrolled in the SUNRISE-PD study, and will be presented as a poster during the Movement Disorders Session on Parkinson's Disease Emerging Therapeutics, on Monday, April 20, from 5:00 PM–6:00 PM CT.

Topline results from the SUNRISE-PD study are expected in mid‑2026.

The AAN is the leading voice in brain health. As the world’s largest association of neurologists and neuroscience professionals with 44,000+ members, the AAN offers access to continuing education, essential practice tools, research grants, networking and advocacy opportunities, and more.

Affiliations: ¹BioVie, Inc, ²Perissos, Inc., ³Princeton Pharmatech, ⁴Medical University of South Carolina

About Bezisterim

Bezisterim (NE3107) is an oral drug that crosses the blood-brain barrier and works to reduce inflammation and improve insulin sensitivity without suppressing the immune system and with a low risk of drug-drug interactions. By modulating key pathways involved in neuroinflammation (ERK, NFκB, TNF-α), bezisterim may have therapeutic potential in several disease indications, including Parkinson’s disease, Long COVID, and Alzheimer’s disease.

In Parkinson’s disease, BioVie has already completed a Phase 2 study that showed patients with moderate- to severe Parkinson’s taking bezisterim with levodopa had better motor control and fewer morning symptoms compared to those taking levodopa alone. Few drug-related side effects were observed. The current SUNRISE-PD just completed enrolling 60 patients to evaluate whether bezisterim alone can help improve motor and non-motor symptoms for Parkinson’s patients who have not been treated with carbidopa/levodopa. Topline results are expected in mid‑2026.

For Long COVID, the ADDRESS-LC trial is enrolling about 200 patient to evaluate if bezisterim can reduce brain fog, fatigue, and other lingering neurological symptoms associated with Long Covid, which are believed to be triggered by persistent circulation of spike protein fragments that trigger inflammation via NFκB activation (which bezisterim has been shown to modulate). Topline data is expected mid-2026.

In Alzheimer’s disease, BioVie has conducted both Phase 2 and Phase 3 trials. Early results suggest improvements in cognition and biomarkers, supporting further trials to evaluate its potential as a therapy for the six million Americans living with Alzheimer’s.

About BioVie Inc.
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage biopharmaceutical company focused on developing therapies for neurological disorders and advanced liver disease. Its lead candidate, bezisterim (NE3107), targets neuroinflammation and insulin resistance, which are believed to be key drivers of Alzheimer’s and Parkinson’s disease. Bezisterim is also being studied for long COVID, where persistent inflammation is thought to underlie symptoms such as brain fog and fatigue.

In liver disease, BioVie is advancing BIV201, a continuous infusion of terlipressin treatment that has received FDA Orphan and Fast Track designations. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis, and the Company plans to study BIV201 in a Phase 3 trial for the reduction of further decompensation in patients with cirrhosis and ascites. For more information, visit www.bioviepharma.com.

For Investor Relations Inquiries:	For Media Inquiries:
Contact: Chuck Padala Managing Director, LifeSci Advisors, LLC chuck@lifesciadvisors.com	Contact: Melyssa Weible Managing Partner, Elixir Health Public Relations  mweible@elixirhealthpr.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What will BioVie (BIVI) present about NE3107 at AAN on April 20, 2026?

BioVie will present baseline demographics and characteristics from SUNRISE-PD in a poster presentation. According to BioVie, the poster summarizes initial patient enrollment data and will appear during the Movement Disorders Session on Parkinson's Disease Emerging Therapeutics.

When are topline results from BioVie's SUNRISE-PD study (BIVI) expected?

Topline results from SUNRISE-PD are expected in mid‑2026. According to BioVie, the company anticipates releasing primary study outcomes around that time, after completion of data collection and analysis.

Where and when will the BIVI SUNRISE-PD poster be shown at the AAN 2026 meeting?

The SUNRISE-PD poster will be shown in Chicago on April 20, 2026 from 5:00 PM–6:00 PM CT. According to BioVie, it is part of the Movement Disorders Session on Parkinson's Disease Emerging Therapeutics.

What is the focus of BioVie's SUNRISE-PD study (BIVI) presented at AAN 2026?

SUNRISE-PD evaluates bezisterim (NE3107) in early Parkinson’s disease with initial baseline patient data. According to BioVie, the abstract covers demographics and characteristics of enrolled patients from the study.

How significant is AAN for BioVie (BIVI) to present SUNRISE-PD data in April 2026?

AAN is a high‑visibility forum with 44,000+ neurology professionals, offering broad exposure for early trial data. According to BioVie, presenting at AAN helps share SUNRISE-PD findings with clinical and research communities.